Company intelligence / Profile preview

Tolmar Pharmaceuticals Canada

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Tolmar commercializes globally approved specialty injectables (notably leuprolide acetate/ELIGARD® for prostate cancer and FENSOLVI® for CPP) and participates in clinical trials for new indications and delivery innovations. New partnerships (e.g., with DelSiTech) expand long-acting technology capabilities, supporting its global product portfolio and strategic growth[1][2][3][8][9][11].

Therapeutic areas: OncologyEndocrinology
Modalities: Small moleculePeptideSynthetic peptideHormoneSteroidBiologicLong-acting injectable
Industry: Biotech

Partnerships

DelSiTech (Silica Matrix drug delivery platform)Sanofi (Eligard commercialization transition in Canada)Eton Pharmaceuticals (ALKINDI SPRINKLE co-promotion)UpScriptHealth (Jatenzo collaboration)

Beyond the preview

Go deeper on Tolmar Pharmaceuticals Canada.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tolmar Pharmaceuticals Canada.

Explore the full profile